



PCT A/D 581-40

10/472626

DT15 Rec'd PCT/PTO 22 SEP 2003  
Q77487

MODIFIED Form PTO-1595 (Rev. 10/02)		RECORDATION FORM COVER SHEET PATENTS ONLY		U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office	
To the Director of the U.S. Patent and Trademark Office: Please record the attached original documents or copy thereof.					
1. Name of conveying party(ies): Hiroaki MITSUYA Kenji MAEDA Shiro SHIBAYAMA Yoshikazu TAKAOKA		2. Name and address of receiving party(ies): ONO PHARMACEUTICAL CO., LTD. 1-5, Doshomachi 2-chome, Chuo-ku, Osaka-shi, OSAKA 541-8526 JAPAN			
Additional name(s) of conveying party(ies) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		11-20-2003  102605482			
3. Nature of conveyance: <input checked="" type="checkbox"/> Assignment <input type="checkbox"/> Merger <input type="checkbox"/> Security Agreement <input type="checkbox"/> Change of Name <input type="checkbox"/> Other					
Execution Date: September 5, 5, 8, and 8, 2003		Additional name(s) & address(es) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No			
4. Application number(s) or patent number(s): If this document is being filed together with a new application, the execution date of the application is: September 5, 5, 8, and 8, 2003 A. Patent Application No.(s) 10472626 B. Patent No.(s)					
Additional numbers attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No					
5. Name and address of party to whom correspondence concerning document should be mailed: SUGHRUE MION, PLLC WASHINGTON OFFICE 23373 CUSTOMER NUMBER		6. Total number of applications and patents involved: 1			
		7. Total fee (37 CFR 3.41): \$40.00 <input checked="" type="checkbox"/> Enclosed. <input type="checkbox"/> Authorized to be charged to Deposit Account No. 19-4880. The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.			
		8. Deposit Account Number: 19-4880 (Attach duplicate copy of this page if paying by deposit account)			
DO NOT USE THIS SPACE					
9. Statement and signature. <i>To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.</i>  Reg. No. 32,197 September 22, 2003 Date G1 Mark Boland					
Total number of pages including cover sheet, attachments, and documents: 3					
Mail documents to be recorded with required cover sheet information to: MAIL STOP ASSIGNMENT RECORDATION SERVICES Director of the U.S. Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450					

PATENT  
REEL: 014702 FRAME: 0350

## ASSIGNMENT

Whereas, I/we Hiroaki MITSUYA and Kenji MAEDA, both of Kumamoto, Japan and  
Shiro SHIBAYAMA and Yoshikazu TAKAOKA, both of Osaka, Japan

hereinafter called assignor(s), have invented certain improvements in  
PHARMACEUTICAL COMPOSITION COMPRISING, AS AN ACTIVE INGREDIENT,  
TRIAZASPIRO[5.5]UNDECANE DERIVATIVE  
and executed an application for Letters Patent of the United States of America therefor on

September 5, 2003 ; and

Whereas, ONO PHARMACEUTICAL CO., LTD. of  
1-5, Doshomachi 2-chome, Chuo-ku, Osaka-shi, OSAKA 541-8526 JAPAN

(assignee), desires to acquire the entire right, title and interest in the application and invention, and to  
any United States patents to be obtained therefor;

Now therefore, for valuable consideration, receipt whereof is hereby acknowledged,

I/We, the above named assignor(s), hereby sell, assign and transfer to the above named  
assignee, its successors and assigns, the entire right, title and interest in the application and the  
invention disclosed therein for the United States of America, including the right to claim priority under  
35 U.S.C. § 119, and I/we request the Director – U.S. Patent and Trademark Office to issue any  
Letters Patent granted upon the invention set forth in the application to the assignee, its successors  
and assigns; and I/we will execute without further consideration all papers deemed necessary by the  
assignee in connection with the United States application when called upon to do so by the assignee.

I/We hereby authorize and request my/our attorneys SUGHRUE MION, PLLC of 2100  
Pennsylvania Avenue, N.W., Washington, D.C. 20037-3213 to insert here in parentheses (Application  
number \_\_\_\_\_, filed \_\_\_\_\_) the filing date and application  
number of said application when known.

Date: September 5, 2003 s/ 

Date: September 5, 2003 s/ Kenji Maeda

Date: s/ \_\_\_\_\_

Date: s/ \_\_\_\_\_

Date: s/ \_\_\_\_\_

(Legalization not required for recording but is prima facie evidence of execution under 35 U.S.C. §261)

# ASSIGNMENT

Whereas, I/we Hiroaki MITSUYA and Kenji MAEDA, both of Kumamoto, Japan and  
Shiro SHIBAYAMA and Yoshikazu TAKAOKA, both of Osaka, Japan

hereinafter called assignor(s), have invented certain improvements in  
PHARMACEUTICAL COMPOSITION COMPRISING, AS AN ACTIVE INGREDIENT,  
TRIAZASPIRO[5.5]UNDECANE DERIVATIVE  
and executed an application for Letters Patent of the United States of America therefor on

September 8, 2003 ; and

Whereas, ONO PHARMACEUTICAL CO., LTD. of  
1-5, Doshomachi 2-chome, Chuo-ku, Osaka-shi, OSAKA 541-8526 JAPAN

(assignee), desires to acquire the entire right, title and interest in the application and invention, and to  
any United States patents to be obtained therefor;

Now therefore, for valuable consideration, receipt whereof is hereby acknowledged,

I/We, the above named assignor(s), hereby sell, assign and transfer to the above named  
assignee, its successors and assigns, the entire right, title and interest in the application and the  
invention disclosed therein for the United States of America, including the right to claim priority under  
35 U.S.C. § 119, and I/we request the Director – U.S. Patent and Trademark Office to issue any  
Letters Patent granted upon the invention set forth in the application to the assignee, its successors  
and assigns; and I/we will execute without further consideration all papers deemed necessary by the  
assignee in connection with the United States application when called upon to do so by the assignee.

I/We hereby authorize and request my/our attorneys SUGHRUE MION, PLLC of 2100  
Pennsylvania Avenue, N.W., Washington, D.C. 20037-3213 to insert here in parentheses (Application  
number \_\_\_\_\_, filed \_\_\_\_\_) the filing date and application  
number of said application when known.

Date: s/ \_\_\_\_\_

Date: s/ \_\_\_\_\_

Date: September 8, 2003 s/ Shiro Shibayama

Date: September 8, 2003 s/ Yoshikazu Takaoka

Date: s/ \_\_\_\_\_

(Legalization not required for recording but is prima facie evidence of execution under 35 U.S.C. §261)